INFARCT SIZE-LIMITING PROPERTIES OF RO-40-5967, A NOVEL NONDIHYDROPYRIDINE CALCIUM-CHANNEL, IN ANESTHETIZED RATS - COMPARISON WITH VERAPAMIL

被引:15
作者
RICHARD, V
TRON, C
BLANC, T
THUILLEZ, C
机构
[1] UNIV ROUEN, SCH MED, IFRMP, VACOMED, DEPT PHARMACOL, ROUEN, FRANCE
[2] ROUEN HOSP, ROUEN, FRANCE
关键词
ISCHEMIA; REPERFUSION; CALCIUM ANTAGONISTS; INFARCT SIZE;
D O I
10.1097/00005344-199504000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We assessed the hemodynamic and infarct size (IS)-limiting effects of the new calcium antagonist Ro 40-5967 in a rat model of ischemia/reperfusion and compared the effects of Ro 40-5967 with those of verapamil. Open-chest rats underwent 20-min coronary occlusion followed by 2-h reperfusion. We determined area at risk (AAR) and IS at the end of reperfusion by India ink injection and triphenyltetrazolium chloride (TTC) staining, using computerized analysis of enlarged sections after color video acquisition. Ro 40-5967 [0.3 mg/kg intravenous (i.v.) bolus 15 min before ischemia + 0.3 mg/kg/h i.v. infusion] and verapamil (0.3 mg/kg followed by 0.3 mg/kg/h) induced significant and similar limitations of IS (percentage of AAR: controls, 61.2 +/- 3.5%; Ro 40-5967, 41.0 +/- 4.0%; verapamil, 43 +/- 4.8%; both p < 0.01 versus controls). The IS-limiting effect of Ro 40-5967 was not accompanied by any changes in heart rate (HR) or rate pressure product (RPP), whereas verapamil decreased both HR and RPP throughout ischemia/reperfusion. In contrast, verapamil administered at a lower dose (0.03 mg/kg followed by 0.03 mg/kg/h), which induced hemodynamic effects similar to those of Ro 40-5967, had no effect on IS (57.1 +/- 5.2, p = NS). Furthermore, additional hemodynamic studies performed in noninfarcted rats showed that Ro 40-5967 exerted negative inotropic effects that were less marked than those induced by verapamil. Therefore, Ro 40-5967 exerts myocardial protective effects that appear to be independent of changes in systemic hemodynamics or myocardial contractility.
引用
收藏
页码:552 / 557
页数:6
相关论文
共 32 条
[1]  
ALPS BJ, 1983, ARZNEIMITTELFORSCH, V33-1, P868
[2]   RO 40-5967, A NOVEL CALCIUM-CHANNEL ANTAGONIST, PROTECTS AGAINST VENTRICULAR-FIBRILLATION [J].
BILLMAN, GE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 229 (2-3) :179-187
[3]   EFFECTS OF DILTIAZEM ON EXTENT OF ULTIMATE MYOCARDIAL INJURY RESULTING FROM TEMPORARY CORONARY-ARTERY OCCLUSION IN DOGS [J].
BUSH, LR ;
ROMSON, JL ;
ASH, JL ;
LUCCHESI, BR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (02) :285-296
[4]   THE STRUCTURALLY NOVEL CA-2+ CHANNEL BLOCKER RO 40-5967, WHICH BINDS TO THE [H-3] DESMETHOXYVERAPAMIL RECEPTOR, IS DEVOID OF THE NEGATIVE INOTROPIC EFFECTS OF VERAPAMIL IN NORMAL AND FAILING RAT HEARTS [J].
CLOZEL, JP ;
VENIANT, M ;
OSTERRIEDER, W .
CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 (03) :731-736
[5]   EFFECTS OF RO-40-5967, A NOVEL CALCIUM-ANTAGONIST, ON MYOCARDIAL-FUNCTION DURING ISCHEMIA INDUCED BY LOWERING CORONARY PERFUSION-PRESSURE IN DOGS - COMPARISON WITH VERAPAMIL [J].
CLOZEL, JP ;
BANKEN, L ;
OSTERRIEDER, W .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 14 (05) :713-721
[6]  
EZZAHER A, 1991, J PHARMACOL EXP THER, V257, P466
[7]   DILTIAZEM INCREASES LATE-ONSET CONGESTIVE-HEART-FAILURE IN POSTINFARCTION PATIENTS WITH EARLY REDUCTION IN EJECTION FRACTION [J].
GOLDSTEIN, RE ;
BOCCUZZI, SJ ;
CRUESS, D ;
NATTEL, S .
CIRCULATION, 1991, 83 (01) :52-60
[8]   REDUCTION OF EXERCISE-INDUCED REGIONAL CONTRACTILE DYSFUNCTION IN DOGS USING A NOVEL CALCIUM-CHANNEL BLOCKER (RO-40-5967) [J].
GUTH, BD .
CARDIOVASCULAR DRUGS AND THERAPY, 1992, 6 (02) :167-171
[9]   THE NOVEL CALCIUM-ANTAGONIST RO-40-5967 LIMITS MYOCARDIAL INFARCT SIZE IN THE DOG [J].
HEIDE, RSV ;
SCHWARTZ, LM ;
REIMER, KA .
CARDIOVASCULAR RESEARCH, 1994, 28 (10) :1526-1532
[10]   EFFECTS OF NIFEDIPINE ON MYOCARDIAL PERFUSION AND ISCHEMIC-INJURY IN DOGS [J].
HENRY, PD ;
SHUCHLEIB, R ;
BORDA, LJ ;
ROBERTS, R ;
WILLIAMSON, JR ;
SOBEL, BE .
CIRCULATION RESEARCH, 1978, 43 (03) :372-380